Any current/future new fundraising through debt or equity?

The transcript does not explicitly mention any current or planned fundraising through debt or equity. The company has taken an ECB (External Commercial Borrowing) for acquisition-related funding, with the drawdown temporarily parked for future use. Debt repayment schedule is outlined, with term loan repayments of approximately Rs. 24 crores in H2 FY24 and Rs. 45-50 crores annually over the next two years, indicating planned debt reduction. Management mentioned they have not confirmed any M&A but are always looking for opportunities, suggesting potential future strategic investments. No direct

Future growth expectations in sales/revenue/volumes?

Domestic business growth: Confident of achieving 14%-16% growth in H2 FY24, driven by both seasonal products and sub-chronic therapies like stomatology and ophthalmics. Europe business: Maintaining guidance of Rs. 375-380 crores for FY24 with expectation of order normalization after recent overstocking issues. US business: Expect continued strong performance with sustainable profit share from products like Brinzolamide in Q3 and Q4. Emerging markets: Significant growth observed (71.6% rise in Q2 revenues), expected to continue. API business: Strong growth (95.6% increase in Q2), indicating rob

Future growth expectations in earnings/operating earnings/profits/EPS?

The management aims to achieve a 17% EBITDA margin for FY24, despite remediation and R&D expenses impacting the first half. They expect better margin performance in the second half, driven by improved international formulation sales and seasonal uptick in domestic products. Domestic business growth in H2 is expected at 14%-16%, led by sub-chronic therapies (stomatology, ophthalmology) and a seasonal recovery in anti-infectives and respiratory segments. Europe business is expected to recover, maintaining full-year guidance of around Rs. 375-380 crores despite Q2 disruptions. US business

Current/ Expected Orderbook/ Pending Orders?

The company has good visibility for orders ahead, especially in the European markets after a temporary decline. The recent slowdown in European orders was due to overstocking by the front-end partner but orders have restarted, with manufacturing and dispatch planned for November and December. There has been no loss of orders in the European business; the company expects to meet or slightly exceed the Rs. 375-380 crore guidance for Europe. In the US business, while specific profit-share details remain confidential, the business model ensures ongoing dossier income and profit sharing contr

IN US

Sale is live|00:00:00left today

Indoco Remedies LtdQ3 FY23Pharmaceuticals & Biotechnology

Indoco Remedies Ltd Q3 FY23 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹237Market Cap: ₹2.1K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 2

Fundraise

Yes

Order

N/A

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 3

→Domestic business growth: Confident of achieving 14%-16% growth in H2 FY24, driven by both seasonal products and sub-chronic therapies like stomatology and ophthalmics.
→Europe business: Maintaining guidance of Rs. 375-380 crores for FY24 with expectation of order normalization after recent overstocking issues.
→US business: Expect continued strong performance with sustainable profit share from products like Brinzolamide in Q3 and Q4.
→Emerging markets: Significant growth observed (71.6% rise in Q2 revenues), expected to continue.
→API business: Strong growth (95.6% increase in Q2), indicating robust volume expansion.
→Overall company outlook: Well-positioned with ongoing capacity expansions, new product launches, ANDA filings, and improved operational efficiencies to support volume and value growth.

Margin guidance

Category 2

→The management aims to achieve a 17% EBITDA margin for FY24, despite remediation and R&D expenses impacting the first half.
→They expect better margin performance in the second half, driven by improved international formulation sales and seasonal uptick in domestic products.
→Domestic business growth in H2 is expected at 14%-16%, led by sub-chronic therapies (stomatology, ophthalmology) and a seasonal recovery in anti-infectives and respiratory segments.
→Europe business is expected to recover, maintaining full-year guidance of around Rs. 375-380 crores despite Q2 disruptions.
→US business growth is sustainable in Q3 and Q4, though exact profit share details remain confidential.
→Cost optimizations, including operational efficiencies and reduced overhead, are underway to improve profitability.
→EPS for H1 FY24 was 6.41 (down from 9.56 last year), but better profitability and revenue growth are expected to drive future EPS improvement.

3 more insights locked — sign up free to unlock

Fundraise plans

Yes

→The transcript does not explicitly mention any current or planned fundraising through debt or equity.
→The company has taken an ECB (External Commercial Borrowing) for acquisition-related funding, with the drawdown temporarily parked for future use.
→Debt repayment schedule is outlined, with term loan repayments of approximately Rs. 24 crores in H2 FY24 and Rs. 45-50 crores annually over the next two years, indicating planned debt reduction.
→Management mentioned they have not confirmed any M&A but are always looking for opportunities, suggesting potential future strategic investments.
→No direct indication of fresh equity fundraising was provided during the call.

Order book

→The company has good visibility for orders ahead, especially in the European markets after a temporary decline.
→The recent slowdown in European orders was due to overstocking by the front-end partner but orders have restarted, with manufacturing and dispatch planned for November and December.
→There has been no loss of orders in the European business; the company expects to meet or slightly exceed the Rs. 375-380 crore guidance for Europe.
→In the US business, while specific profit-share details remain confidential, the business model ensures ongoing dossier income and profit sharing contributing to revenues.
→One more quarter is expected to have some impact of remediation costs, but the overall order backlog remains stable and sustainable through Q3 and Q4.
→Good visibility of sustained international formulations growth supports orderbook confidence.

Capex plans

Yes

- Recent expansions include a Waluj plant expansion to meet volume demand from emerging and Indian markets. - Upgrades at the API facility in Patalganga, including a larger quality control laboratory. - Contemplation of a new business in pharmacovigilance via AnaCipher CRO in Hyderabad. - Ongoing IT projects across HR, operations, sales, and quality assurance at manufacturing sites. - Initiatives underway to increase batch size, improve yield, and reduce overheads especially related to human capital. - Greenfield and Brownfield expansion programs are underway at multiple sites. - Recent drawdown of an ECB (External Commercial Borrowing) to cover cash requirements for acquisition-related purposes, funds currently parked temporarily for future use. - While no concrete M&A is currently in execution, the company is actively scouting for good brands in India and quality facilities internationally. - Investments aimed at improving efficiency and competitiveness of products. Overall, the company is actively investing in capacity, capabilities, and potential strategic acquisitions.

How does Indoco Remedies Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Indoco Remedies Ltd

Rev 3Mar 2

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like Indoco Remedies Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio